Today's Wall St Journal reports that the new chemo drug Jevtana, manufactured by the French drug company Sanofi-Aventis has received FDA approval under its priority review program, 3 months ahead of schedule. Its safety & effectiveness were established in a single 755-patient study. The goal of the study was human survival time. Jevtana along with a steroid achieved a survival time of 15.1 months, compared with only 12.7 months achieved with chemo drug mitroxantrone plus the same steroid
No comments:
Post a Comment